Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life

This publication has 10 references indexed in Scilit:

• Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy
  Clinical Therapeutics, 1995
• Ondasetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial
  Cancer, 1994
• Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclophosphamide-based Chemotherapy
  Annals of Internal Medicine, 1993
• Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: A randomized, single-blind, multicentre study
  Clinical Oncology, 1992
• Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
  Journal of Clinical Oncology, 1992
• Quality of life consequences of chemotherapy-induced emesis
  Quality of Life Research, 1992
• Emesis as a Complication of Cancer Chemotherapy: Pathophysiology, Importance, and Treatment
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1992
• Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
  Journal of Clinical Oncology, 1990
• Advances in anti-emetic therapy
  Cancer Treatment Reviews, 1984
• Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
  Journal of Clinical Oncology, 1984